Our Story
We are the translational research division of Scripps Research, with a team of highly experienced scientists dedicated to progressing therapies from discovery into clinical trials. Our infrastructure and expertise extend from high-throughput screening and protein engineering to pharmacology and clinical development.
Overview
The Calibr-Skaggs Institute for Innovative Medicines is the leading nonprofit translational research center focused on preclinical drug discovery and early-stage clinical research. Peter Schultz, President and CEO of Scripps Research, founded Calibr as an independent, nonprofit institute in 2012 based on the principle that creating new medicines can be accelerated by pairing world-class biomedical research with state-of-the-art drug discovery and development capabilities.
Calibr-Skaggs scientists have broad expertise identifying and developing small-molecule drugs, biologics and cell therapies, and then advancing these therapies to the clinic. This allows the creation of therapeutic candidates for a range of indications spanning oncology, regenerative medicine, neurological diseases, metabolic diseases and infectious diseases. By leveraging its unique infrastructure, strategic partnerships and generous philanthropic support, eleven programs have been advanced into clinical development and an additional five into investigational new drug (IND)-enabling studies—an unprecedented accomplishment in the nonprofit world.
Calibr officially became a division of Scripps Research in 2018 as a self-funded, translational research center to create a unique vision for Scripps Research as a world leader in biomedical research that translates scientific discovery into medicines that impact patients. Its state-of-the-art infrastructure and translational capabilities help amplify the impact of discoveries made in Scripps Research laboratories, while interdisciplinary scientists also advance internally developed programs forward. The institute is central to Scripps Research’s innovative funding strategies that provide a sustainable model for science and biomedical research and that amplifies investment in science and grows with success. In 2023, Calibr was renamed the Calibr-Skaggs Institute for Innovative Medicines in honor of transformational support from the Skaggs family through the ALSAM Foundation.
Calibr-Skaggs works with several academic, nonprofit and pharmaceutical industry partners to advance therapies, including the Bill & Melinda Gates Foundation and AbbVie.
Explore opportunities to join us in our quest to develop novel therapeutics targeting a broad spectrum of unmet medical needs.